These include studies demonstrating the effectiveness of dipeptidyl peptidase-4 (DPP-4) inhibitors in patients with renal disease [16] and reports showing improvements in postprandial hyperglycemia with nateglinide and/or acarbose in patients with rheumatoid arthritis or collagen diseases [17]. The gene discussed is DPP4; the disease is kidney disorder.